Assess whether RWE can replace or only supplement an RCT (988c30)

Situation

A mid-size sponsor after a complete response letter cannot treat a literature paper the 505(b)(2) package leans on getting retracted as color commentary on 505(b)(2) literature-to-product bridge table. CMC change-control owner must close RWE can replace or from that extract under Pharma & Life Sciences / Pharmacovigilance.

Decision

CMC change-control owner in a mid-size sponsor after a complete response letter must choose RWE can replace / Only supplement an RCT using 505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• 505(b)(2) literature-to-product bridge table reads as RWE can replace once a literature paper the 505(b)(2) package leans on getting retracted is lined up to the same Pharma & Life Sciences population.
• 505(b)(2) literature-to-product bridge table is closer to Only supplement an RCT after a literature paper the 505(b)(2) package leans on getting retracted; RWE can replace would over-claim this Pharmacovigilance extract.
• A dual reading is still live in 505(b)(2) literature-to-product bridge table for CMC change-control owner in a mid-size sponsor after a complete response letter.
• 505(b)(2) literature-to-product bridge table is missing the fact CMC change-control owner needs after a literature paper the 505(b)(2) package leans on getting retracted; stop this Pharma & Life Sciences close.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on RWE can replace or.
• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• For this Pharma & Life Sciences Pharmacovigilance file, read 505(b)(2) literature-to-product bridge table against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move RWE can replace or for CMC change-control owner.

Recommendation

Choose RWE can replace / Only supplement an RCT on this Pharma & Life Sciences / Pharmacovigilance packet (505(b)(2) literature-to-product bridge table after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option 505(b)(2) literature-to-product bridge table can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for CMC change-control owner in a mid-size sponsor after a complete response letter.